Earnings Surprise Leads to 7% Surge... 380 Billion Won Invested in Addiction Treatment Company

Indivior Pharmaceuticals Inc. (NASDAQ: INDV) jumped 6.81% on the Nasdaq, closing at $30.75. With trading volume above its average, the company’s market capitalization rose by roughly $280 million in a single day, about KRW 380 billion.

In its fourth quarter of fiscal 2025, Indivior reported earnings per share of $0.82, well above the market estimate of $0.65, and revenue of $358 million, beating consensus forecasts. The company also said it would issue up to $550 million of convertible bonds maturing in 2031 with a 0.625% coupon, with proceeds earmarked for debt repayment and share repurchases.

Headquartered in Virginia, Indivior is a specialty pharmaceutical firm focused on addiction treatments, with flagship products including the monthly injectable Sublocade and Suboxone for opioid use disorder. Since spinning off from the U.K.’s Reckitt Benckiser, the company has been broadening its U.S. listing and shifting its headquarters and governance structure to the United States.